CTOs on the Move

Anixa Biosciences

www.anixa.com

 
Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.anixa.com
  • 3150 Almaden Expressway
    San Jose, CA USA 95118
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Anixa Biosciences raised $10M on 03/22/2021

Similar Companies

Siolta Therapeutics

Siolta Therapeutics is an early stage, venture-backed biotech company focused on developing therapeutic microbial consortia to prevent and treat inflammatory diseases.

TECHNE CORP /MN/

TECHNE CORP /MN/ is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IMIDomics

IMIDomics is a biotechnology company focused on Patient-Centric drug discovery for immune-mediated inflammatory diseases (IMIDs). Our goal is to discover new and impactful IMID drugs by focusing on carefully selected patients, and stratifying populations to identify those most likely to respond. IMIDomics is powered by a unique Clinical Discovery EngineTM, which integrates and analyzes proprietary clinical, epidemiological and patient-derived biomolecular datasets, generated in partnership with the Vall d`Hebron Institute of Research, to establish a deeper understanding of IMID diseases. By doing so, IMIDomics has identified previously unrecognized targets, six of which have been selected for development. By relying on access to well-defined patients and their clinically relevant samples, IMIDomics enhances the probability of successful IMID drug discovery and development for those in need.

Talaris Therapeutics

Talaris Therapeutics is a late-clinical stage biotechnology company based in Boston, MA and Louisville, KY. Talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. The company was founded on technology discovered and developed by Dr. Suzanne Ildstad and operates its own cell processing facility in Louisville. Talaris is backed by leading life sciences investors Blackstone Life Sciences, Longitude Capital and Qiming Venture Partners USA.

Revance

Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, including muscle movement disorders and pain. The company`s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comprehensive pipeline based upon its peptide technology, including injectable and topical formulations of daxibotulinumtoxinA.